MAZE · Maze Therapeutics Inc
United States · RS rating 47 · As of 2026-10-14
| Price | 26.23 USD |
|---|---|
| 1-day change | -1.6% |
| RS rating (overall / 1M / 3M / 12M) | 47 / 92 / 49 / 34 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 33 / 19 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +1.5% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +49.4% |
| Market cap (USD) | $1.4B |